Increase in testosterone levels is related to a lower risk of conversion of prediabetes to manifest diabetes in prediabetic males.
Fatty liver
Insulin resistance
Prediabetes
Sex-specific differences
Testosterone
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
25
09
2020
accepted:
27
05
2021
pubmed:
6
7
2021
medline:
8
2
2022
entrez:
5
7
2021
Statut:
ppublish
Résumé
Testosterone plays an important role in the regulation of glucose metabolism. While earlier studies have shown that it has a protective effect in males, unfavorable effects of testosterone on glucose metabolism have been reported in females; however, whether there is a sex-specific relationship between testosterone and glucose metabolism in patients with prediabetes has not been investigated in detail hitherto. This cross-sectional analysis investigated 423 males and 287 females with diagnosed prediabetes. Detailed assessment of their metabolic profiles was performed, including a 2‑h oral glucose tolerance test (OGTT), HbA1c levels, calculation of insulin resistance with homeostatic model assessment for insulin resistance (HOMA-IR), assessment of lipid metabolism, anthropometric parameters and the fatty liver index (FLI). By using Spearman's correlation test, we investigated the sex-specific relationship between testosterone and metabolism in the prediabetic individuals. In the present study, prediabetic females (mean age 58.6 years, confidence interval [CI: 57.6 y; 59.5 y]) were characterized by lower fasting plasma glucose levels (104.2 mg/dl [CI: 103.0 mg/dl; 105.4 mg/dl] vs. 106.9 mg/dl [CI: 106.0 mg/dl; 107.8 mg/dl]) and a lower FLI (49.5 [CI: 45.7; 53.2] vs. 58.8 [CI: 55.8; 61.8]), but presented with a higher risk of developing manifest type 2 diabetes in the next 10 years (FINDRISK score: 17.6 [CI: 17.1; 18.1] vs. 16.1 [CI: 15.7; 16.5]) when compared to prediabetic males (mean age: 58.04 years [CI: 57.0 y; 59.1 y]). Testosterone was negatively related to insulin resistance (HOMA-IR: Spearman's ρ: -0.33, p < 0.01), 2‑h stimulated glucose levels during the OGTT (ρ = -0.18, p < 0.01), HbA1c levels (ρ = -0.13, p < 0.05), FLI and BMI in prediabetic males; however, no relationship between testosterone and metabolic parameters could be found in prediabetic females. The increase of testosterone levels in males was related to a more favorable glucose metabolism, including lower HbA1c, lower stimulated glucose levels and higher insulin sensitivity; however, in prediabetic females, testosterone was not related to glucose metabolism.
Sections du résumé
BACKGROUND
BACKGROUND
Testosterone plays an important role in the regulation of glucose metabolism. While earlier studies have shown that it has a protective effect in males, unfavorable effects of testosterone on glucose metabolism have been reported in females; however, whether there is a sex-specific relationship between testosterone and glucose metabolism in patients with prediabetes has not been investigated in detail hitherto.
METHODS
METHODS
This cross-sectional analysis investigated 423 males and 287 females with diagnosed prediabetes. Detailed assessment of their metabolic profiles was performed, including a 2‑h oral glucose tolerance test (OGTT), HbA1c levels, calculation of insulin resistance with homeostatic model assessment for insulin resistance (HOMA-IR), assessment of lipid metabolism, anthropometric parameters and the fatty liver index (FLI). By using Spearman's correlation test, we investigated the sex-specific relationship between testosterone and metabolism in the prediabetic individuals.
RESULTS
RESULTS
In the present study, prediabetic females (mean age 58.6 years, confidence interval [CI: 57.6 y; 59.5 y]) were characterized by lower fasting plasma glucose levels (104.2 mg/dl [CI: 103.0 mg/dl; 105.4 mg/dl] vs. 106.9 mg/dl [CI: 106.0 mg/dl; 107.8 mg/dl]) and a lower FLI (49.5 [CI: 45.7; 53.2] vs. 58.8 [CI: 55.8; 61.8]), but presented with a higher risk of developing manifest type 2 diabetes in the next 10 years (FINDRISK score: 17.6 [CI: 17.1; 18.1] vs. 16.1 [CI: 15.7; 16.5]) when compared to prediabetic males (mean age: 58.04 years [CI: 57.0 y; 59.1 y]). Testosterone was negatively related to insulin resistance (HOMA-IR: Spearman's ρ: -0.33, p < 0.01), 2‑h stimulated glucose levels during the OGTT (ρ = -0.18, p < 0.01), HbA1c levels (ρ = -0.13, p < 0.05), FLI and BMI in prediabetic males; however, no relationship between testosterone and metabolic parameters could be found in prediabetic females.
CONCLUSION
CONCLUSIONS
The increase of testosterone levels in males was related to a more favorable glucose metabolism, including lower HbA1c, lower stimulated glucose levels and higher insulin sensitivity; however, in prediabetic females, testosterone was not related to glucose metabolism.
Identifiants
pubmed: 34223999
doi: 10.1007/s00508-021-01903-1
pii: 10.1007/s00508-021-01903-1
pmc: PMC8813729
doi:
Substances chimiques
Blood Glucose
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-6Informations de copyright
© 2021. The Author(s).
Références
Andrology. 2019 Mar;7(2):148-155
pubmed: 30666808
Diabetes Care. 2019 Jun;42(6):1104-1111
pubmed: 30862651
J Sex Med. 2018 Aug;15(8):1117-1124
pubmed: 30078463
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Diabetes Care. 2011 Apr;34(4):828-37
pubmed: 21386088
JAMA. 2006 Mar 15;295(11):1288-99
pubmed: 16537739
Cell Metab. 2016 May 10;23(5):837-51
pubmed: 27133133
J Cell Biol. 2018 Jul 2;217(7):2273-2289
pubmed: 29622564
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Endocr Rev. 2016 Jun;37(3):278-316
pubmed: 27159875
J Endocrinol. 2014 Jan 27;220(3):R37-55
pubmed: 24353306
J Clin Endocrinol Metab. 2018 Feb 1;103(2):681-688
pubmed: 29253154
Andrology. 2017 Jan;5(1):49-57
pubmed: 27792861
Front Endocrinol (Lausanne). 2019 Mar 13;10:90
pubmed: 30930846
Hum Reprod Update. 2018 Jan 1;24(1):86-105
pubmed: 29136166
Hum Reprod Update. 2010 Jul-Aug;16(4):347-63
pubmed: 20159883
Diab Vasc Dis Res. 2005 May;2(2):67-72
pubmed: 16305061
J Sex Med. 2011 Jan;8(1):272-83
pubmed: 20807333
Nat Rev Endocrinol. 2013 Aug;9(8):479-93
pubmed: 23797822
N Engl J Med. 2005 Mar 24;352(12):1223-36
pubmed: 15788499
Lancet Diabetes Endocrinol. 2020 Feb;8(2):134-149
pubmed: 31635966
Nat Rev Endocrinol. 2014 Oct;10(10):624-36
pubmed: 25022814
Nat Rev Endocrinol. 2009 Dec;5(12):673-81
pubmed: 19859074
PLoS One. 2013 Sep 12;8(9):e74173
pubmed: 24069277
Trends Endocrinol Metab. 2016 Dec;27(12):844-855
pubmed: 27640750
J Am Coll Cardiol. 2016 Feb 9;67(5):545-57
pubmed: 26846952
Diabetologia. 2020 Mar;63(3):453-461
pubmed: 31754750